scispace - formally typeset
P

Pramod K. Srivastava

Researcher at University of Connecticut

Publications -  405
Citations -  29058

Pramod K. Srivastava is an academic researcher from University of Connecticut. The author has contributed to research in topics: Heat shock protein & Antigen. The author has an hindex of 79, co-authored 390 publications receiving 27330 citations. Previous affiliations of Pramod K. Srivastava include Gujarat University & Memorial Sloan Kettering Cancer Center.

Papers
More filters
Journal ArticleDOI

CD11c+ MHCIIlo GM-CSF-bone marrow-derived dendritic cells act as antigen donor cells and as antigen presenting cells in neoepitope-elicited tumor immunity against a mouse fibrosarcoma.

TL;DR: It is shown that dendritic cells but not macrophages possess superior adjuvanticity, and that the CD11c+ MHCIIlo sub-set, distinguishable by a distinct transcriptional profile including a higher expression of heat shock protein receptors CD91 and LOX1, mannose receptors and TLRs, is significantly superior to the CD 11c+MHCIIhi sub- set.
Journal Article

A Multicentre, Open label, Randomized, Comparative, Parallel Group, Active-controlled, Phase III Clinical Trial to Evaluate Safety and Efficacy of Arbekacin Sulphate Injection versus Vancomycin Injection in Patients Diagnosed with MRSA Infection.

TL;DR: Overall cure rate of MRSA infection (clinical as well as microbiological cure) was comparable in both the treatment groups i.e. 97.5% in Arbekacin group and 100% in Vancomycin group, suggesting that ArbekACin can be considered as safe and effective alternative to vancomYcin in the management of MR SA infections.
Journal Article

Prognostic factors in Guillain-Barre' syndrome.

TL;DR: Prospective prognostic evaluation of various clinical and investigative parameters in 24 patients of Guillain-Barre' syndrome revealed poor prognosis in patients having rapid onset of illness, severe degree of paralysis and muscle wasting, prolonged period of peak paralysis lasting for more than 2 weeks and delayed onset of recovery not commencing within 3 weeks from the onset of weakness.
Journal ArticleDOI

Immune response to mutant neo-antigens: Cancer's lessons for aging

TL;DR: It is hypothesized that, at least under inflammatory conditions, immune responses against such neo-antigens may lead to the elimination or functional impairment of normal cells, thus contributing to aging.
Patent

Identification of tumor-protective epitopes for the treatment of cancers

TL;DR: In this article, a novel index called the Differential Agretopic Index (DAI) for the epitope which allows prediction of whether immunization with a particular epitope will be protective against the tumor was proposed.